{"id":55795,"date":"2023-04-13T17:03:27","date_gmt":"2023-04-13T15:03:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\/"},"modified":"2023-04-13T17:03:27","modified_gmt":"2023-04-13T15:03:27","slug":"nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\/","title":{"rendered":"Nucleix to Premiere Data on its EpiCheck\u00ae Lung Cancer Atlas at the 2023 American Association for Cancer Research Annual Meeting"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>Presentations will highlight company\u2019s multiomic, genome-wide discovery platform with <\/i><i>methylation at its core, to identify blood-based biomarkers focused on early-stage lung cancer detection<\/i><\/p>\n<p>SAN DIEGO &amp; REHOVOT, Israel&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnucleix.com%2F&amp;esheet=53380851&amp;newsitemid=20230413005579&amp;lan=en-US&amp;anchor=Nucleix&amp;index=1&amp;md5=6993b8903671eb4312a87c07a0c0f3f4\" rel=\"nofollow noopener\" shape=\"rect\">Nucleix<\/a>, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, will premiere data from its early lung cancer detection discovery platform, the Nucleix EpiCheck\u00ae Lung Atlas, at the American Association for Cancer Research (AACR) Annual Event in Orlando, April 14-19. The proprietary Lung Atlas was constructed and developed as part of a multi-institutional effort to map epigenetic and genomic changes associated with early-stage lung cancer, particularly stage I disease.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230413005579\/en\/839844\/4\/nucleix_owler_20190920_133824_large.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230413005579\/en\/839844\/21\/nucleix_owler_20190920_133824_large.jpg\"><\/a><\/p>\n<p>\n<b>Presentations at AACR include:<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.abstractsonline.com%2Fpp8%2F%23%21%2F10828%2Fpresentation%2F4349&amp;esheet=53380851&amp;newsitemid=20230413005579&amp;lan=en-US&amp;anchor=Development+of+a+Genome-Wide+Multiomic+Atlas+of+Early-Stage+Lung+Cancer+Enables+Identification+of+Novel+Methylation+Biomarkers+for+Disease+Detection+Beyond+TCGA&amp;index=2&amp;md5=7b6f940a8b94da6cb430d9d36829430a\" rel=\"nofollow noopener\" shape=\"rect\">Development of a Genome-Wide Multiomic Atlas of Early-Stage Lung Cancer Enables Identification of Novel Methylation Biomarkers for Disease Detection Beyond TCGA<\/a><\/p>\n<p>Session date and time: April 17 at 1:30pm ET<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.abstractsonline.com%2Fpp8%2F%23%21%2F10828%2Fpresentation%2F8108&amp;esheet=53380851&amp;newsitemid=20230413005579&amp;lan=en-US&amp;anchor=Machine-Learning-Based+Epigenetic+Detection+of+Early-Stage+Lung+Cancers+Using+the+EpiCheck+Liquid+Biopsy+Platform&amp;index=3&amp;md5=a7e662e9b5b40127a3938aa0053ef375\" rel=\"nofollow noopener\" shape=\"rect\">Machine-Learning-Based Epigenetic Detection of Early-Stage Lung Cancers Using the EpiCheck Liquid Biopsy Platform<\/a><\/p>\n<p>Session date and time: April 18 at 1:30pm ET<\/li>\n<\/ul>\n<p>\n\u201cWhen lung cancer is detected early, it is more likely that patients will survive the disease,\u201d said Chris Hibberd, CEO, Nucleix. \u201cCurrently though, most patients are diagnosed with late-stage cancer, even though research has shown that five-year survival rates are up to 10 times greater when lung cancer is detected early.<sup>i<\/sup> Results demonstrate the strength of Nucleix\u2019s Lung EpiCheck<sup> <\/sup>assay<sup> <\/sup>and our differentiated approach for the discovery and identification of novel biomarkers for non-invasive lung cancer screening. We are leveraging these findings to advance a new generation of Lung EpiCheck, which incorporates novel markers from the Lung Atlas and is optimized to detect minute cancer epigenetic signals with greater sensitivity. The next step is well underway as we evaluate the new assay in the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04968548%3Fterm%3Dnucleix%26draw%3D2%26rank%3D2&amp;esheet=53380851&amp;newsitemid=20230413005579&amp;lan=en-US&amp;anchor=Sightline+Trial&amp;index=4&amp;md5=072ad095b70f79e3eff394345c1bc2b3\" rel=\"nofollow noopener\" shape=\"rect\">Sightline Trial<\/a>, a 5,000 patient multicenter study in high-risk current and former smokers.\u201d<\/p>\n<p>\nCurrently there are limited options for early lung cancer detection and only 10% of the nearly 15 million high-risk smokers recommended to receive low-dose CT imaging adhere to current guidelines.<sup>ii<\/sup> The Lung Atlas will aid in Nucleix\u2019s development of the next generation of clinical assays. Nucleix\u2019s Lung EpiCheck analyzes changes in multiple methylation markers to screen for lung cancer using a non-invasive blood sample, with a focus on testing individuals who are at high-risk based on smoking history. Lung EpiCheck has been optimized to focus on sensitivity, so that physicians have a better chance of early detection and patients have a better chance of successful treatment.<\/p>\n<p>\nLearn more about <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnucleix.com%2Flung-epicheck%2F&amp;esheet=53380851&amp;newsitemid=20230413005579&amp;lan=en-US&amp;anchor=Nucleix%26%238217%3Bs+Lung+EpiCheck&amp;index=5&amp;md5=c9b98ee9fa6e0ffaea0580bbc3249920\" rel=\"nofollow noopener\" shape=\"rect\">Nucleix\u2019s Lung EpiCheck<\/a>.<\/p>\n<p>\n<b>About Nucleix<\/b><\/p>\n<p>\nNucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection at a time when intervention can bring the greatest impact for patients. Leveraging NGS and PCR-based technologies, the Company\u2019s pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. The Company\u2019s non-invasive EpiCheck<sup>\u00ae<\/sup> delivers highly accurate and sensitive results, while providing a seamless testing option for physicians, patients, and the healthcare system. The Company is building an EpiCheck<sup>\u00ae<\/sup> franchise, beginning with the Bladder EpiCheck<sup>\u00ae<\/sup> kit, CE-marked and available in Europe for primary and recurrent bladder cancer and upper tract urinary cancer. The Company is advancing its Lung EpiCheck<sup>\u00ae<\/sup> test towards commercialization for high-risk individuals, while evaluating additional tests for other high-risk diseases. For more information, please visit: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nucleix.com&amp;esheet=53380851&amp;newsitemid=20230413005579&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.nucleix.com&amp;index=6&amp;md5=2f834aa4670fae0f79a5863c6f18441f\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.nucleix.com<\/a>.<\/p>\n<p>\n<sup>i<\/sup> American Lung Association. Lung Cancer Fact Sheet. 2020; <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lung.org%2Flung-health-diseases%2Flung-disease-lookup%2Flung-cancer%2Fresource-library%2Flung-cancer-fact-sheet&amp;esheet=53380851&amp;newsitemid=20230413005579&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.lung.org%2Flung-health-diseases%2Flung-disease-lookup%2Flung-cancer%2Fresource-library%2Flung-cancer-fact-sheet&amp;index=7&amp;md5=9dd3343e53945b33ddb509d075c61a22\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.lung.org\/lung-health-diseases\/lung-disease-lookup\/lung-cancer\/resource-library\/lung-cancer-fact-sheet<\/a><\/p>\n<p>\n<sup>ii<\/sup> U.S. Preventive Services Task Force. Lung Cancer: Screening. 2021; <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.uspreventiveservicestaskforce.org%2Fuspstf%2Frecommendation%2Flung-cancer-screening&amp;esheet=53380851&amp;newsitemid=20230413005579&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.uspreventiveservicestaskforce.org%2Fuspstf%2Frecommendation%2Flung-cancer-screening&amp;index=8&amp;md5=713cdb05896c30118b1b085e51a78a9c\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/lung-cancer-screening<\/a><\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nJake Robison<br \/>\n<br \/>Evoke Canale<br \/>\n<br \/>(619) 849-5383<br \/>\n<br \/><a target=\"_blank\" href=\"mailto:j&#97;&#107;&#101;&#46;&#114;&#111;&#98;&#105;&#115;&#111;&#x6e;&#x40;&#x65;&#x76;&#x6f;&#x6b;&#x65;&#x67;&#x72;&#x6f;&#x75;&#x70;&#x2e;&#x63;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x6a;&#97;k&#x65;&#46;r&#x6f;&#x62;&#105;&#x73;&#x6f;&#110;&#64;&#x65;&#118;o&#x6b;&#x65;&#103;&#x72;&#x6f;&#117;p&#x2e;&#99;o&#x6d;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Presentations will highlight company\u2019s multiomic, genome-wide discovery platform with methylation at its core, to identify blood-based biomarkers focused on early-stage lung cancer detection SAN DIEGO &amp; REHOVOT, Israel&#8211;(BUSINESS WIRE)&#8211;Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, will premiere data from its early lung cancer detection discovery platform, the Nucleix EpiCheck\u00ae &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55795","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nucleix to Premiere Data on its EpiCheck\u00ae Lung Cancer Atlas at the 2023 American Association for Cancer Research Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nucleix to Premiere Data on its EpiCheck\u00ae Lung Cancer Atlas at the 2023 American Association for Cancer Research Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Presentations will highlight company\u2019s multiomic, genome-wide discovery platform with methylation at its core, to identify blood-based biomarkers focused on early-stage lung cancer detection SAN DIEGO &amp; REHOVOT, Israel&#8211;(BUSINESS WIRE)&#8211;Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, will premiere data from its early lung cancer detection discovery platform, the Nucleix EpiCheck\u00ae ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-13T15:03:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230413005579\/en\/839844\/21\/nucleix_owler_20190920_133824_large.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Nucleix to Premiere Data on its EpiCheck\u00ae Lung Cancer Atlas at the 2023 American Association for Cancer Research Annual Meeting\",\"datePublished\":\"2023-04-13T15:03:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\\\/\"},\"wordCount\":601,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230413005579\\\/en\\\/839844\\\/21\\\/nucleix_owler_20190920_133824_large.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\\\/\",\"name\":\"Nucleix to Premiere Data on its EpiCheck\u00ae Lung Cancer Atlas at the 2023 American Association for Cancer Research Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230413005579\\\/en\\\/839844\\\/21\\\/nucleix_owler_20190920_133824_large.jpg\",\"datePublished\":\"2023-04-13T15:03:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230413005579\\\/en\\\/839844\\\/21\\\/nucleix_owler_20190920_133824_large.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230413005579\\\/en\\\/839844\\\/21\\\/nucleix_owler_20190920_133824_large.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nucleix to Premiere Data on its EpiCheck\u00ae Lung Cancer Atlas at the 2023 American Association for Cancer Research Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nucleix to Premiere Data on its EpiCheck\u00ae Lung Cancer Atlas at the 2023 American Association for Cancer Research Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Nucleix to Premiere Data on its EpiCheck\u00ae Lung Cancer Atlas at the 2023 American Association for Cancer Research Annual Meeting - Pharma Trend","og_description":"Presentations will highlight company\u2019s multiomic, genome-wide discovery platform with methylation at its core, to identify blood-based biomarkers focused on early-stage lung cancer detection SAN DIEGO &amp; REHOVOT, Israel&#8211;(BUSINESS WIRE)&#8211;Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, will premiere data from its early lung cancer detection discovery platform, the Nucleix EpiCheck\u00ae ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-13T15:03:27+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230413005579\/en\/839844\/21\/nucleix_owler_20190920_133824_large.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Nucleix to Premiere Data on its EpiCheck\u00ae Lung Cancer Atlas at the 2023 American Association for Cancer Research Annual Meeting","datePublished":"2023-04-13T15:03:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\/"},"wordCount":601,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230413005579\/en\/839844\/21\/nucleix_owler_20190920_133824_large.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\/","name":"Nucleix to Premiere Data on its EpiCheck\u00ae Lung Cancer Atlas at the 2023 American Association for Cancer Research Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230413005579\/en\/839844\/21\/nucleix_owler_20190920_133824_large.jpg","datePublished":"2023-04-13T15:03:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230413005579\/en\/839844\/21\/nucleix_owler_20190920_133824_large.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230413005579\/en\/839844\/21\/nucleix_owler_20190920_133824_large.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/nucleix-to-premiere-data-on-its-epicheck-lung-cancer-atlas-at-the-2023-american-association-for-cancer-research-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Nucleix to Premiere Data on its EpiCheck\u00ae Lung Cancer Atlas at the 2023 American Association for Cancer Research Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55795"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55795\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}